All Companies articles – Page 15
-
NewsMetrion Biosciences appoints Lee Patterson as CEO
Metrion Biosciences is set to accelerate its global expansion and enhance its leadership in ion channel drug discovery services.
-
WebinarUnprecedented fragment-based screening using Spectral Shift for GPCRs
In this webinar, we will present how challenging recombinant protein such as GPCRs are produced and characterised and how biophysics participates in GPCRs hit finding and hit confirmation.
-
WebinarRapid functional cell-based activity profiling of multi-receptor targeted anti-obesity therapies
Eurofins Discovery’s Luke Oostdyk, PhD, will highlight anti-obesity target combination therapies and cell-based assays ideal for testing functional activity, specificity, potency and signalling mechanisms of desired therapies against multiple disease-relevant targets.
-
WebinarCRISPR™ MDCKII cell lines development for bioavailability and DDI assessments
Join this webinar to hear from Eurofins Discovery on the latest offerings for drug-drug interaction assessments using CRISPR KO/KI MDCKII cell lines
-
WebinarSAFIRE: AI predicted ADME for drug discovery: leveraging BioPrint
Join Dr Carleton Sage to learn about predicting ADME properties as a key approach to improving the efficiency of small molecule drug discovery. AI ADME model development approaches and case studies within drug discovery projects will be discussed.
-
WebinarBiophysics in kinase drug discovery: FBS to PROTAC® ternary complex characterisation
Watch this webinar to learn how biophysics can be used in different cascade strategies where the goal is to identify and characterise fragments, compounds or active degraders targeting PIM3 kinase.
-
WebinarSH2 domains as a target class in cancer and inflammation
New SH2 domain binding assays developed by Eurofins Discovery have been launched to support drug discovery initiatives in the protein-protein interaction space and in targeted protein degradation. We present small molecule case study data for important targets within this target class including STAT Transcription factors and Kinases.
-
WebinarCardiac and vascular safety liabilities using totality of evidence approach
US-FDA recommend integration of both preclinical (S7B) and clinical (E14) data to improve risk assessment, reduce reliance on TQT clinical studies, streamlined drug-development, simplified decision-making processes, effective risk-communication.